Liquid Genomics

Torrance, United States Founded: 2013 • Age: 13 yrs Acquired By NantHealth
Blood-based molecular diagnostics for cancer are developed and offered.

About Liquid Genomics

Liquid Genomics is a Healthcare company based in Torrance (United States) founded in 2013, and was acquired by NantHealth in February 2018. Blood-based molecular diagnostics for cancer are developed and offered. Liquid Genomics has raised $4.86 million across 3 funding rounds from investors including NantHealth. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its competitors include GRAIL, Color and Earli; 3 of its 3 listed competitors have raised funding.

Company details

Liquid Genomics offers blood-based molecular diagnostics for cancer. Its flagship product analyzes bloods samples for circulating tumor DNA and RNA using PCR to monitor efficacy of chemotherapy treatments and risk of cancer recurrence. Current markers tested are variants of EGFR, ALK, KRAS, BRAF, NRAS, PD-L1, AR-V7 and ROS1.

  • Headquarters Torrance, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website liquidgenomics.com
  • Social X
  • Acquired by NantHealth (Feb 2018)
Key Metrics
  • Total Equity Funding
    $4.86M (USD)

    in 3 rounds

  • Latest Funding Round
    $1.63M (USD), Series A

    Jan 2017

  • Investors
  • Acquired by
    NantHealth

    (Feb 2018)

Funding Insights of Liquid Genomics

Liquid Genomics has successfully raised a total of $4.86M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.63 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $4.86M
  • Total Rounds 3
  • Last Round Series A β€” $1.63M

All 3 funding rounds of Liquid Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2017$1.63MSeries A––
–
May 2014$3.24MSeries A––
–
May 2014Debt – Conventional––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Liquid Genomics

Liquid Genomics has secured backing from 1 investor. Prominent investors backing the company include NantHealth.

All
InvestorDescriptionFounded YearDomainLocation
Bioinformatics platforms are provided for cancer treatment identification.
2007nanthealth.comEl Segundo, United States
Premium access

Investor details for Liquid Genomics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Liquid Genomics

4 dated milestones of Liquid Genomics across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Liquid Genomics is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series A, of $1.6M.
  4. Exit Acquired by NantHealth.

Competitors of Liquid Genomics

Liquid Genomics has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Color and Earli.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
grail.com2016Menlo Park, United States$2B491
Circulating tumor DNA is screened for early cancer detection.
color.com2013Burlingame, United States$491.44M687
Cancer care is delivered through a virtual clinic by Color.
earli.com2018San Francisco, United States$40M38
Early cancer detection tests are developed using synthetic biomarkers.
Premium access

Detailed competitors of Liquid Genomics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Liquid Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Liquid Genomics

Liquid Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Liquid Genomics is headquartered in Torrance, United States. It is registered at Torrance, California, United States.

Liquid Genomics is a funded company, having raised a total of $4.86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.24M, raised on May 2014.

Liquid Genomics offers blood-based molecular diagnostics for cancer. Its flagship product analyzes bloods samples for circulating tumor DNA and RNA using PCR to monitor efficacy of chemotherapy treatments and risk of cancer recurrence. Current markers tested are variants of EGFR, ALK, KRAS, BRAF, NRAS, PD-L1, AR-V7 and ROS1.

Liquid Genomics's top competitors include GRAIL, Earli and Color.

Liquid Genomics has 1 investor. Key investors include NantHealth.

Yes. Liquid Genomics was acquired by NantHealth in February 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available